<table id="table14" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 14. Mean<linkhtml href="#footnote-1">*</linkhtml> Pharmacokinetic Parameters in Healthy Volunteers and Adult Patients With Epilepsy</caption>
<col align="left" span="1" valign="top" width="32%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<col align="center" span="1" valign="top" width="17%"></col>
<tbody>
<tr>
<th colspan="1">Adult Study Population</th>
<th colspan="1">Number of Subjects</th>
<th colspan="1">T<sub>max</sub>: Time of Maximum Plasma Concentration (hr)</th>
<th colspan="1">t<sub>½</sub>: Elimination Half-life (hr)</th>
<th colspan="1">Cl/F: Apparent Plasma Clearance (mL/min/kg)</th>
</tr>
<tr>
<td>
<content stylecode="bold">Healthy volunteers taking no other medications:</content>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>179</td>
<td>2.2<br/>(0.25-12.0)</td>
<td>32.8<br/>(14.0-103.0)</td>
<td>0.44<br/>(0.12-1.10)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>36</td>
<td>1.7<br/>(0.5-4.0)</td>
<td>25.4<br/>(11.6-61.6)</td>
<td>0.58<br/>(0.24-1.15)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Healthy volunteers taking valproate:</content>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>6</td>
<td>1.8<br/>(1.0-4.0)</td>
<td>48.3<br/>(31.5-88.6)</td>
<td>0.30<br/>(0.14-0.42)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>18</td>
<td>1.9<br/>(0.5-3.5)</td>
<td>70.3<br/>(41.9-113.5)</td>
<td>0.18<br/>(0.12-0.33)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking valproate only:</content>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>4</td>
<td>4.8<br/>(1.8-8.4)</td>
<td>58.8<br/>(30.5-88.8)</td>
<td>0.28<br/>(0.16-0.40)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone<linkhtml href="#footnote-2">†</linkhtml> plus valproate:</content>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>25</td>
<td>3.8<br/>(1.0-10.0)</td>
<td>27.2<br/>(11.2-51.6)</td>
<td>0.53<br/>(0.27-1.04)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone<footnoteref idref="t14ft2"></footnoteref>:</content>
</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-dose lamotrigine</td>
<td>24</td>
<td>2.3<br/>(0.5-5.0)</td>
<td>14.4<br/>(6.4-30.4)</td>
<td>1.10<br/>(0.51-2.22)</td>
</tr>
<tr>
<td>Multiple-dose lamotrigine</td>
<td>17</td>
<td>2.0<br/>(0.75-5.93)</td>
<td>12.6<br/>(7.5-23.1)</td>
<td>1.21<br/>(0.66-1.82)</td>
</tr>
</tbody>
</table>